Today Dr. Melamede Makes A Statement Addressing Veterans Coping With Post Traumatic Stress Disorder (PTSD) A National Disgrace; Cannabis Science To Launch A Program To Work With Veterans Who Use Medical Cannabis To Cope With PTSD

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science Inc. (OTCBB: CBIS) an emerging pharmaceutical cannabis company is proud to announce that it will be launching a program to work with veterans who use medical cannabis to cope with Post Traumatic Stress Disorder (PTSD).

A Statement by Dr. Robert Melamede Ph.D. Cannabis Science President and CEO

"I want to take this opportunity to inform you that in addition our other studies, one of our first clinical trials will focus on improving the health of those most worthy of help, our military veterans.

Sadly, significant numbers of recent veterans returning from the Iraqi and Afghani conflicts, as well as our Vietnam vets, are suffering from Post Traumatic Stress Disorder (PTSD). The excessive stress that leads to this condition has also resulted in alcohol and drug abuse, associated family problems, and an unacceptably high suicide rate.

One of the ubiquitous biochemical balancing acts carried out by our endocannabinoid system is to help us forget unpleasant memories. Our cannabis extract based oral medication is the natural solution for helping restore a state of health to our veterans. It helps them to relax, reduces their pain, and gives them the peaceful night of sleep. Our cannabis-based medicine provides a holistic biochemical push to help restore a healthier state.

Our veterans sacrificed life and limb to protect the freedoms that the very heart of our country. They too frequently come back disabled and are offered copious quantities of addictive drugs and ineffective antidepressants. Many have discovered that medical marijuana is a safer and more effective aid for reducing their discomfort. We at Cannabis Science believe that just as our veterans have fought to preserve our freedom, we must fight to preserve their freedom. Many Veterans have found that cannabis-based medicines are the most effective means of relieving their health issues. They have earned the right to make that decision. We are confident, based on what the veterans are telling us, that we will have a successful clinical trial.

I want to end this press release by thanking all of our investors for the confidence that they have placed in us and in what we are trying to accomplish. Again, thank you for your support."

About Cannabis Science, Inc.

Dr. Melamede is the former Chairman (ret) of the Biology Department at the University of Colorado (Colorado Springs).

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.